Brainsway (BWAY) has released an update.
BrainsWay Ltd. has launched a multicenter clinical trial to assess a new accelerated treatment protocol for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system for major depressive disorder, which promises a shorter acute treatment phase compared to the standard protocol. The innovative trial, which involves over 100 patients, is designed to potentially increase convenience and appeal of Deep TMS™ therapy for depression. BrainsWay aims to solidify its position as a leader in noninvasive neurostimulation treatments with this initiative.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.
